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Background: Cystic pancreatic lesions are increasingly more frequent detected clinical entities. Mucinous cystic
neoplasm (MCN) is a hormone-related pancreatic tumor (HRTP) with a strong predominance in young and middle-aged
females.
Case presentation: Here, we present the case of a 31-year-old surgically transgendered female-to-male patient
with a history of alcoholic pancreatitis, on chronic testosterone therapy. He was found to have a pancreatic MCN
and underwent distal pancreatectomy and splenectomy.
Conclusion: To our knowledge, this is the first reported case of a transgender patient with a history of hormone
replacement therapy (HRT) and pancreatic MCN. We consider possible mechanisms for the pathogenesis to explain this
patient’s neoplasm.
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Mucinous cystic neoplasm (MCN) is a hormone-related
pancreatic tumor (HRTP) with a strong predominance
in young and middle-aged females [1]. In 1996, the
World Health Organization and Armed Forces Institute
of Pathology provided a formal distinction between
intraductal papillary mucinous neoplasms (IPMN) and
MCN, stressing the importance of the presence of ovar-
ian stroma to diagnose MCN. The validity of this dis-
tinction has been confirmed in subsequent studies [2].
However, the criteria for distinguishing MCN from other
mucinous tumors remain debated [2]. These neoplasms
have risk for malignancy and require either close radio-
logical follow-up or resection depending on their size
and morphological characteristics [3, 4].
The exact mechanism of how sex hormones affect the
development of pancreatic tumors is not entirely under-
stood. Pancreatic tissue expresses estrogen receptors [5],
and there are contributory reports of MCN development
during pregnancy [6–10] and in post-menopausal women
on hormone replacement therapy (HRT) [11]. There is* Correspondence: wilbur.bowne@drexelmed.edu
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receptors [5]. However, reports of pancreatic MCNs in
males are limited and of the reports of men with
MCN, most have a history of pancreatitis and/or aber-
rant hormone levels and sexual phenotypic characteris-
tics [1, 12, 13]. The expression of estrogen and
progesterone receptors in MCN among some male pa-
tients is perplexing [1]. There are also rare reports of
pancreatic MCNs in men or post-menopausal women,
which do not show the characteristic ovarian-like
stroma. Some suggest that such tumors be called “in-
determinate mucin-producing cystic neoplasms” so as
to maintain the requirement that MCNs are defined by
ovarian-like stroma [11].
Here, we present the case of a 31-year-old surgically
transgendered female-to-male patient with a history of
alcoholic pancreatitis, on chronic testosterone therapy.
He was found to have a pancreatic MCN and underwent
distal pancreatectomy and splenectomy. To our know-
ledge, this is the first reported case of a transgender pa-
tient on HRT with pancreatic MCN. We provide a case
presentation and propose possible mechanisms, based
upon our review of the literature, for the pathogenesis of
this patient’s neoplasm.ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Abdominal CT with pancreatic protocol showing cystic
pancreatic mass. a Arterial phase CT axial slice through the pancreatic
body shows a cystic mass within the body region. b Coronal
reconstruction portal venous phase shows a cystic mass confined
to the pancreatic parenchyma
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The patient is a 31-year-old surgically transgendered,
female-to-male patient with a history of multiple prior
admissions for alcoholic pancreatitis. He was on chronic,
long-term testosterone therapy. He presented complain-
ing of pain in the mid-epigastrium, which had worsened
over the prior months, with occasional radiation to the
back and shoulders and post-prandial worsening of pain.
He denied nausea, vomiting, diarrhea, weight change, or
constipation.
Additional past medical history was significant for
anxiety and attention deficit hyperactivity disorder. His
surgical history included laparoscopic cholecystectomy,
tonsillectomy, bilateral mastectomy, total bilateral hys-
terectomy, and bilateral salpingo-oophorectomy. His
family history included leukemia, diabetes mellitus, and
cholecystitis. His medications included testosterone
cypionate, bupropion, escitalopram, hyoscyamine sulfate,
omeprazole, and pancrelipase. He was a former smoker
with history of polysubstance abuse including chronic
alcoholism.
His physical examination was otherwise non-contributory.
Serum CA19-9 level was moderately elevated at 72 u/ml
[reference range <34], lipase was elevated at 128 u/l
[ref 7–60], and amylase was within the normal range at
51 u/l [ref: 20–101]. Serum IgG4 was negative. Com-
puted tomography (CT) scan of the abdomen and pel-
vis with pancreatic protocol demonstrated a pancreatic
body cystic mass (Fig. 1a, b). Endoscopic ultrasound
(EUS) confirmed a 30 × 33 mm round multi-septated
mass in the pancreatic body suggestive of an MCN
(Fig. 2). Aspirated cyst fluid analysis revealed an ele-
vated CEA level of 745 ng/mL.
Of note, 6 years prior to presentation at our institution,
the patient was being followed with serial cross-sectional
imaging, demonstrating a pancreatic body cystic lesion.
Importantly, during this interval period of time, the lesion
was noted to alternately increase and decrease in size.
Surgical management included distal pancreatectomy
and splenectomy. Specimens were sent for pathologic
examination. Serial sectioning of the formalin-fixed spe-
cimen revealed a 2 × 1.8 × 1.2 cm septated cyst with a
tan-pink, smooth, and glistening inner lining, filled with
clear, thin fluid. The cyst was located 0.9 cm from the
proximal pancreatic resection margin, 6.7 cm from the
splenic hilum, and 0.1 cm from the nearest posterior as-
pect. It abutted but did not involve the main pancreatic
duct (Fig. 3a, b). Microscopic examination showed that
the cyst was lined by cuboidal or mucin-producing epi-
thelium and surrounded by the ovarian-like stroma,
which was immunohistochemically positive for estrogen
and progesterone receptors (Fig. 4a–d). These character-
istics are consistent with the diagnosis of MCN. The pa-
tient’s post-operative course was complicated by a peri-pancreatic abscess and fistula, which resolved following
endoscopic placement of a pancreatic ductal stent. On
yearly follow-up, the patient had no evidence of recur-
rent disease.
Discussion
Pancreatic MCN is a HRTP with predominance in females
[1], characterized by ovarian-like stroma [4]. Figure 5 out-
lines the possible mechanisms for the pathogenesis of
pancreatic MCN in our patient, which is likely multifac-
torial. Investigators have speculated about the interaction
between HRT and the development of hormone-related
Fig. 2 FNA-EUS showing hypo-echoic pancreatic mass, arrow
A
B
Fig. 3 Gross pathology of the tumor. a A distal portion of pancreas
with an attached intact spleen, white arrow delineates pancreatic
MCN. b A gross section of pancreatic cyst, white arrow delineates
pancreatic cyst wall
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there are several case reports describing the occurrence of
prostate cancer after many decades of estrogen therapy
[14, 15]. The exact role that estrogen plays in the develop-
ment of pancreatic MCN is not entirely understood [16].
However, the pancreas is known to express estrogen re-
ceptors and binding proteins [5]. Normal pancreatic tissue
can convert estrone and estrone sulfate into active 17-
beta-estradiol, and estrogen is believed to be necessary for
pancreatic enzyme synthesis [5]. There are contributory
reports of MCN development during pregnancy [6–10]
and in post-menopausal women on HRT [11].
One explanation for the pathogenesis of pancreatic
MCN expressing ovarian-like stroma is that genital
gland and dorsal pancreatic buds are adjacent during the
course of development such that primary yolk cells may
be implanted in the pancreas [16]. This mechanism is
plausible in the patient presented here. Another explan-
ation is that immature pancreatic stroma, which ex-
presses sex hormone receptors, responds to female
hormones resulting in cystic change and progression
[16]. In either case, estrogen is required to stimulate tis-
sue proliferation. The patient discussed here is female-
to-male transgendered on chronic testosterone therapy.
It is plausible that exogenous testosterone could have
been aromatized to estradiol. This would be particularly
true if the testosterone dosing was relatively high. Aro-
matase and 5-alpha-reductase have both been identified
in human pancreatic cancer tissue [17]. The former en-
zyme converts testosterone to 5-dihydrotestosterone,
which is a strong androgen, and the latter enzyme converts
testosterone to estradiol as well as delta-4-androstenedione
to estrone. Importantly, notable variations in size of our
patient’s pancreatic MCN may reflect variation in the
Fig. 4 Microscopic pathology of the tumor. a Pancreatic MCN lined by cuboidal epithelium surrounded by the ovarian-like stroma (H&E stain;
c × 1.25). b High-power of pancreatic MCN lined by cuboidal epithelium surrounded by the ovarian-like stroma (H&E stain; d × 10).
c Immunohistochemical staining for estrogen receptor within the MCN stroma (4×). d Immunohistochemical staining for progesterone
receptor within the MCN stroma (4×)
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which lends credence to the hypothesis of hormonal influ-
ences on MCN development and natural history.
The aforementioned embryological mechanism, how-
ever, does not fully account for the albeit rare occur-
rence of pancreatic MCN in men [1, 12]. The literature
concerning pancreatic MCN in males is limited, and it is
possible that the development of MCN in men may not














Fig. 5 Proposed multifactorial mechanisms for pathogenesis of pancreaticwomen [12]. However, of the reports of men with MCN,
most have a history of pancreatitis and/or aberrant
hormone levels and sexual phenotype characteristics
[1, 12, 13]. Moreover, in a recent study that included five
cases of pancreatic MCN along with four cases of pan-
creatic solid pseudopapillary neoplasm (SPN) in men,
hormonal and/or sexual dysfunction was identified in
four of the nine patients [13]. In one case report of a













MCN in a transgender male
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antiprogesterone staining positivity, the authors question
whether or not the presence of female hormone receptors
is adequate to term the tissue of origin to be ovarian.
Pancreatic tissue is also known to express testosterone re-
ceptors as well as estrogen receptors [5]. It has been estab-
lished that there are androgen receptors in pancreatic
cancer, and testosterone has been experimentally shown
to promote growth of pancreatic adenocarcinoma [5].
Chronic pancreatitis is another proposed risk factor
for the development of pancreatic MCN. Wouters et al.
published a case report discussing a 43-year-old man
who had a 10-year history of moderate to high alcohol
intake and chronic pancreatitis that developed a pancre-
atic MCN [1]. Accordingly, a possible mechanism for
the development of pancreatic MCN in chronic alcohol
abusers, male or female, is chronic excess alcohol con-
sumption that results in increased estrogen levels either
via increased peripheral fat conversion of androgen pre-
cursors to estrogen and/or via transient or permanent
liver damage resulting in hormonal imbalance secondary
to disrupted sex steroid metabolic pathways with ele-
vated estrogen levels [1]. The patient presented in this
case had a long history of alcohol abuse.
In terms of management, surgical resection remains the
cornerstone for the treatment of high risk pancreatic cys-
tic lesions. Clinicopathologic factors identified as higher
risk for malignancy among pancreatic cystic neoplasms in-
cludes size greater than 3 cm, presence of septations, a
solid component, and related symptomatology [3, 4].
Conclusion
Here, we present the first reported case of a pancreatic
MCN in a surgically transgendered female-to-male pa-
tient. This patient had a history of alcoholic pancreatitis
and was on chronic, long-term testosterone therapy. We
provide a case presentation and propose possible mecha-
nisms, based upon our review of the literature that could
explain the pathogenesis of his neoplasm. Transgen-
dered patients generally tolerate HRT well. However, this
case suggests that pancreatic neoplasms, in part, may be
susceptible to HRT. This case also illustrates the import-
ance of being aware of special medical and surgical is-
sues in the transgender population.
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